APOL1 Gene Variants in African American Kidney Transplant Recipients
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | June 2011 |
| End Date: | June 2014 |
| Contact: | Anil K Chandraker, MD |
| Email: | achandraker@rics.bwh.harvard.edu |
| Phone: | 617-732-7412 |
Impact of APOL1 Gene Variants in African American Kidney Transplant Recipients: A Study of Clinical Outcomes and Molecular Mechanisms
Aim 1:
Determine if there is an association between the APOL1 risk variants and allograft survival
and function in African Americans
Aim 2:
Determine if there is an association between the presence of APOL1 risk variants in an
African American kidney transplant recipient and the risk of recurrent disease
Aim 3:
Investigate mechanisms of APOL1 associated kidney disease by prospectively following African
American kidney transplant recipients throughout their clinical course.
Determine if there is an association between the APOL1 risk variants and allograft survival
and function in African Americans
Aim 2:
Determine if there is an association between the presence of APOL1 risk variants in an
African American kidney transplant recipient and the risk of recurrent disease
Aim 3:
Investigate mechanisms of APOL1 associated kidney disease by prospectively following African
American kidney transplant recipients throughout their clinical course.
Aim 1:
Inclusion Criteria:
- self-reported African American
- 18 years or older
- kidney transplant within 12 years
Aim 2:
Inclusion Criteria for patients with recurrent disease:
- self-reported African American
- 18 years or older
- kidney transplant within 12 years
- recurrent or de novo glomerular disease on allograft kidney biopsy
Inclusion Criteria for control group:
- self-reported African American
- 18 years or older
- kidney transplant within 12 years
- end stage kidney disease due to glomerular nephritis, clinically diagnosed or by
native kidney biopsy
Exclusion Criteria for control group:
- clinical evidence of recurrent disease (presence of proteinuria, hematuria,
Creatinine >2)
Aim 3:
Inclusion Criteria:
- self-reported African American
- 18 years or older
- scheduled living kidney transplant
We found this trial at
1
site
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
